Microbiome Therapeutics Market Size, Share & Industry | 2031
Microbiome Therapeutics Market Size, Share & Industry | 2031
Segments - Microbiome Therapeutics Market by Types (Microbiome Drugs and Fecal Microbial Transplant), Applications (Diabetes, C. Difficile, Inflammatory Bowel Disease, Crohn’s Disease, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023-2031
Upcoming
| Report ID :HC-2356
| 4.1 Rating
| 68 Reviews
| 182 Pages
| Format :
Report Description
Microbiome Therapeutics Market Outlook 2031
The global microbiome therapeutics market size was USD 94.86 Million in 2022 and is projected to reach USD 1.45 Billion by 2031 register a substantial CAGR 35.42% during the forecast period, 2023-2031. attributed to the rising incidence of diseases owing to microbiota dysbiosis in the gut. The market growth is further attributed to a large amount of funding made for the development studies of various biological drugs.
The microbe with genetic material including fungi, protozoa, bacteria, and viruses that lives inside the gut of a human body is known as the microbiome. They are mostly present in the large intestine. The bacteria present in the microbiome help in the regulation of the immune system, digestion of food, and protection against disease-causing bacteria.
The good health of a person is associated with the gut microbiome. When the number of microorganisms including actinobacteria, bacteroidetes, and firmicute alters, it leads to arthritis, diabetes, gastrointestinal disorders, lung & respiratory disorders, and several other neurological disorders. The reduction of these microorganisms is caused due to unhealthy lifestyles, long-term usage of antibiotics that are of heavy dosage, and increasing age.
Infectious diseases and organisms such as ulcerative colitis and clostridium difficile get induced in the human body due to a decrease in the level of beneficial microbiota.
The COVID-19 pandemic outbreak had a positive impact on the microbiome therapeutics market due to its association with immunity and various respiratory diseases. As per the reports published by the Human Microbiome Journal named “Lung microbiome and COVID-19: Possible Link and Implications,” lung microbiome is expected to have an impact on the seriousness and sensitivity of the pandemic. It is also expected to play a vital role in the prompting of the immune response against this widespread of SARS-CoV-2 infection.
Microbiome Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Rise in prevalence of various diseases that are related to inactive lifestyle and growing number of the geriatric population are anticipated to fuel the market growth during the forecast period.
- Availability of strong pipelines for drugs in the developed regions is expected to drive the market expansion in the coming years.
- Increasing collaborations among several companies for the development and launch of drugs are key factors estimated to propel the market growth.
- Rigid & strict regulations imposed by the government and lack of thorough research are key restraining factors that are expected to hinder the market growth.
- Increasing initiatives taken by governments for raising funds in order to support research work presents a key factor projected to create profitable opportunities for the market expansion.
Scope of the Microbiome Therapeutics Market Report
The report on the global microbiome therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Microbiome Therapeutics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Types (Microbiome Drugs and Fecal Microbial Transplant) and Applications (Diabetes, C. Difficile, Inflammatory Bowel Disease, Crohn’s Disease, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
OpenBiome; Seres Therapeutics; Genome; Enterome Bioscience; Ritter Pharmaceuticals; Second MaaT Pharma; Rebiotix, Inc.; and MicroBiome Therapeutics LLC. |
Microbiome Therapeutics Market Segment Insights
Microbiome drugs is expected to grow at a rapid pace
On the basis of types, the global microbiome therapeutics market is bifurcated into microbiome drugs and fecal microbial transplant. The fecal microbial transplant segment is projected to hold a key market share in the coming years owing to wide recommendation of the therapeutic method by professionals after it was approved by the Investigational New Drug (IND) for biological therapy.
The fecal microbial transplant dominated the market in 2019 as it was the only available option for C. difficile therapeutics. However, the microbiome drugs segment is expected to grow at a rapid pace owing to the presence of product pipelines in phase 2 that are strong and considered to be effective drugs.
Crohn’s disease is estimated to expand at a fast growth rate
Based on applications, the market is segmented into diabetes, C. difficile, inflammatory bowel disease, Crohn’s disease, and others. The C. difficile segment accounted for a large revenue share of the market in 2019 and is projected to exhibit a high CAGR during the forecast period owing to the wide approval of fecal microbial transplant, the only treatment available for it. However, Crohn’s disease is estimated to expand at a fast growth rate in the coming years due to the high presence of drug pipelines for its treatment.
Asia Pacific is anticipated to expand at a considerable CAGR
In terms of regions, the global microbiome therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2019 and is expected to grow substantially during the targeted period attributed to the availability of a large number of patients and presence of a large number of health conscious population.
Moreover, the presence of advanced research facilities and increasing expenditures for healthcare in the region present another key aspects for the regional market expansion. On the other hand, the market of Asia Pacific is anticipated to expand at a considerable CAGR during the forecast period owing to the increasing stability of the economy, increasing awareness regarding therapeutics among professionals, and rise in the number of initiatives by national institutes for biological research in the region.
Segments
The global microbiome therapeutics market has been segmented on the basis of
Types
- Microbiome Drugs
- Fecal Microbial Transplant
Applications
- Diabetes
- C. Difficile
- Inflammatory Bowel Disease
- Crohn’s Disease
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- OpenBiome
- Seres Therapeutics
- Genome
- Enterome Bioscience
- Ritter Pharmaceuticals
- Second MaaT Pharma
- Rebiotix, Inc.
- MicroBiome Therapeutics LLC
Competitive Landscape
Key players competing in the global microbiome therapeutics market are OpenBiome; Seres Therapeutics; Genome; Enterome Bioscience; Ritter Pharmaceuticals; Second MaaT Pharma; Rebiotix, Inc.; and MicroBiome Therapeutics LLC. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.
Some of the key players have received high funding for the development of pipelines for microbiome therapeutics. For example, nearly USD 160 million was invested by Seventure Partners for research in this field.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Microbiome Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Microbiome Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Microbiome Therapeutics Market - Supply Chain
4.5. Global Microbiome Therapeutics Market Forecast
4.5.1. Microbiome Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Microbiome Therapeutics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Microbiome Therapeutics Market Absolute $ Opportunity
5. Global Microbiome Therapeutics Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Microbiome Therapeutics Market Size and Volume Forecast by Types
5.3.1. Microbiome Drugs
5.3.2. Fecal Microbial Transplant
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Microbiome Therapeutics Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Microbiome Therapeutics Market Size and Volume Forecast by Applications
6.3.1. Diabetes
6.3.2. C. Difficile
6.3.3. Inflammatory Bowel Disease
6.3.4. Crohn’s Disease
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Microbiome Therapeutics Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Microbiome Therapeutics Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Microbiome Therapeutics Demand Share Forecast, 2019-2026
8. North America Microbiome Therapeutics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Microbiome Therapeutics Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Microbiome Therapeutics Market Size and Volume Forecast by Types
8.4.1. Microbiome Drugs
8.4.2. Fecal Microbial Transplant
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Microbiome Therapeutics Market Size and Volume Forecast by Applications
8.7.1. Diabetes
8.7.2. C. Difficile
8.7.3. Inflammatory Bowel Disease
8.7.4. Crohn’s Disease
8.7.5. Others
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Microbiome Therapeutics Demand Share Forecast, 2019-2026
9. Latin America Microbiome Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Types
9.4.1. Microbiome Drugs
9.4.2. Fecal Microbial Transplant
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Applications
9.7.1. Diabetes
9.7.2. C. Difficile
9.7.3. Inflammatory Bowel Disease
9.7.4. Crohn’s Disease
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Microbiome Therapeutics Demand Share Forecast, 2019-2026
10. Europe Microbiome Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Microbiome Therapeutics Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Microbiome Therapeutics Market Size and Volume Forecast by Types
10.4.1. Microbiome Drugs
10.4.2. Fecal Microbial Transplant
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Microbiome Therapeutics Market Size and Volume Forecast by Applications
10.7.1. Diabetes
10.7.2. C. Difficile
10.7.3. Inflammatory Bowel Disease
10.7.4. Crohn’s Disease
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Microbiome Therapeutics Demand Share Forecast, 2019-2026
11. Asia Pacific Microbiome Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Types
11.4.1. Microbiome Drugs
11.4.2. Fecal Microbial Transplant
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Applications
11.7.1. Diabetes
11.7.2. C. Difficile
11.7.3. Inflammatory Bowel Disease
11.7.4. Crohn’s Disease
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Microbiome Therapeutics Demand Share Forecast, 2019-2026
12. Middle East & Africa Microbiome Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Types
12.4.1. Microbiome Drugs
12.4.2. Fecal Microbial Transplant
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Applications
12.7.1. Diabetes
12.7.2. C. Difficile
12.7.3. Inflammatory Bowel Disease
12.7.4. Crohn’s Disease
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Microbiome Therapeutics Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Microbiome Therapeutics Market: Market Share Analysis
13.2. Microbiome Therapeutics Distributors and Customers
13.3. Microbiome Therapeutics Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. OpenBiome
13.4.2. Seres Therapeutics
13.4.3. Genome
13.4.4. Enterome Bioscience
13.4.5. Ritter Pharmaceuticals
13.4.6. Second MaaT Pharma
13.4.7. Rebiotix, Inc.
13.4.8. MicroBiome Therapeuti
Methodology
Related Reports
Some other reports from this category!
Our Clients
